You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-VEGFR2 (KDR) Antibodies

Full name:
anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) Antibodies (KDR)
On www.antibodies-online.com are 657 Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) Antibodies from 42 different suppliers available. Additionally we are shipping VEGFR2 Kits (80) and VEGFR2 Proteins (54) and many more products for this protein. A total of 816 VEGFR2 products are currently listed.
Synonyms:
6130401C07, CD309, fk52c05, flk, flk-1, FLK/KDR, flk1, flk1b, kdr, kdra, kdrb, Krd-1, Ly73, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, sVEGFR-2, VEGFR, Vegfr-2, vegfr2, vegfr4, vegr2, wu:fc31a09, wu:fk52c05
list all antibodies Gene Name GeneID UniProt
KDR 16542  
KDR 25589 O08775
KDR 3791 P35968

Show all species

Show all synonyms

All available anti-VEGFR2 Antibodies

Go to our pre-filtered search.

Top referenced anti-VEGFR2 Antibodies

  1. Human Polyclonal VEGFR2 Primary Antibody for FACS, IF - ABIN391979 : Yilmaz, Kliche, Mayr-Beyrle, Fellbrich, Waltenberger: p38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. in Biochemical and biophysical research communications 2003 (PubMed)
    Show all 4 references for ABIN391979

  2. Human Polyclonal VEGFR2 Primary Antibody for IHC (p), WB - ABIN181334 : Quinn, Peters, De Vries, Ferrara, Williams: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. in Proceedings of the National Academy of Sciences of the United States of America 1993 (PubMed)
    Show all 4 references for ABIN181334

  3. Human Polyclonal VEGFR2 Primary Antibody for EIA, IHC (p) - ABIN358131 : Le Boeuf, Houle, Huot: Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. in The Journal of biological chemistry 2004 (PubMed)
    Show all 3 references for ABIN358131

  4. Human Polyclonal VEGFR2 Primary Antibody for WB - ABIN783332 : Zeng, Sanyal, Mukhopadhyay et al.: Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration ... in The Journal of biological chemistry 2001 (PubMed)
    Show all 2 references for ABIN783332

  5. Human Polyclonal VEGFR2 Primary Antibody for IHC (p), WB - ABIN389564 : Wittko, Schänzer, Kuzmichev, Schneider, Shibuya, Raab, Plate: VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of neural progenitors in the rostral migratory stream in vivo. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2009 (PubMed)

  6. Dog (Canine) Polyclonal VEGFR2 Primary Antibody for IHC, WB - ABIN2792307 : Ohsaka, Hirota-Komatsu, Shibata, Ezaki, Shinohara, Yoshida: Specific association of increased vascular endothelial growth factor expression and its receptors with macrophage differentiation of HL-60 leukemia cells. in Biochemical and biophysical research communications 2008 (PubMed)

  7. Human Polyclonal VEGFR2 Primary Antibody for ELISA, WB - ABIN1531411 : Terman, Carrion, Kovacs, Rasmussen, Eddy, Shows: Identification of a new endothelial cell growth factor receptor tyrosine kinase. in Oncogene 1991 (PubMed)

  8. Human Monoclonal VEGFR2 Primary Antibody for EIA, FACS - ABIN155179 : Benzinger, Martiny-Baron, Reusch, Siemeister, Kley, Marmé, Unger, Massing: Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. in Biochimica et biophysica acta 2000 (PubMed)

More Antibodies against VEGFR2 Interaction Partners

Mouse (Murine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. administration of 0.3 IU/mL FSH (show BRD2 Antibodies) during ovarian cryopreservation by vitrification can maintain ovarian survival during ovarian vitrification and increases the blood supply with avascular transplantation via upregulation of Cx43 (show GJA1 Antibodies), Cx37 (show GJA4 Antibodies), and VEGF (show VEGFA Antibodies)/VEGFR2

  2. The data provide new insights for the chaperone function of PDCL3 (show PDCL3 Antibodies) in angiogenesis and the roles of hypoxia and N-terminal methionine acetylation in PDCL3 (show PDCL3 Antibodies) expression and its effect on VEGFR-2.

  3. VEGFA (show VEGFA Antibodies)-induced vascular leakage depends on signaling initiated via the VEGFR2 phosphosite Y949. Abolished Y949 signaling in the mutant Vegfr2(Y949F/Y949F) leads to VEGFA (show VEGFA Antibodies)-resistant endothelial adherens junctions.

  4. These findings together demonstrate the essential role of KDM4A (show KDM4A Antibodies) and KDM4C (show KDM4C Antibodies) in orchestrating mESC differentiation to endothelial cells through the activation of Flk1 and VE-cadherin (show CDH5 Antibodies) promoters, respectively

  5. VEGFA (show VEGFA Antibodies)/VEGFR2 signaling may be essential for podocytes in a normal state.

  6. Thus, (131)I-anti-VEGFR2 cFab (show CFB Antibodies) has the potential to be used for molecularly targeted treatment of hepatocellular carcinoma overexpressing VEGFR2.

  7. tumors in stressed animals demonstrated markedly enhanced expression of VEGFR-2 and L1CAM (show L1CAM Antibodies) mRNA as well as pERK (show EIF2AK3 Antibodies), MMP-2 (show MMP2 Antibodies) and MMP-9 (show MMP9 Antibodies) protein expression.

  8. These results suggest that VEGFR2-mediated Muller cell survival is required for the viability of retinal neurons in diabetes.

  9. data demonstrates that PTK7 (show PTK7 Antibodies) regulates the activity of KDR biphasically by inducing oligomerization of KDR molecules at lower concentrations and by surrounding KDR molecules at higher concentrations.

  10. Our data reveal that AIP1 (show PDCD6IP Antibodies), by inhibiting VEGFR2-dependent signaling in tumor niche, suppresses tumor EMT (show ITK Antibodies) switch, tumor angiogenesis, and tumor premetastatic niche formation to limit tumor growth and metastasis.

Human Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN (show PTEN Antibodies)-deficient glioblastoma.

  2. Findings suggest that VEGF(R)-inhibition may improve the efficacy of intraperitoneal chemotherapy (IPC), particularly for patients for whom a complete cytoreduction might not be feasible.

  3. The genetic statistical interaction between VEGFR-2 (rs2071559, rs11133360) and P2X7R (show P2RX7 Antibodies) (rs3751143, rs208294) genotypes may identify a population of prostate cancer patients with a better prognosis.

  4. MET suppresses VEGFR2 protein by inducing its endoplasmic-reticulum-associated degradation (ERAD), via intracrine VEGF action.

  5. Data suggest that targeting endothelial growth factor (show FGF1 Antibodies) receptor (show RYK Antibodies) 2 (VEGFR-2/KDR) with TTAC-0001 could be a promising approach for cancer treatment.

  6. The data provide new insights for the chaperone function of PDCL3 (show PDCL3 Antibodies) in angiogenesis and the roles of hypoxia and N-terminal methionine acetylation in PDCL3 (show PDCL3 Antibodies) expression and its effect on VEGFR-2.

  7. Meta-analysis. Our finding indicates that VEGFR polymorphism +1192C>T and +1719A>T may be associated with the risk of stroke, but not -604T>C.

  8. miR (show MLXIP Antibodies)-497 inhibits tumor angiogenesis and growth via targeting VEGFR2, indicating miR (show MLXIP Antibodies)-497 can be explored as a potential drug candidate for cancer therapy.

  9. TLR4 knockdown inhibited VEGF signaling through VEGF receptor 2 (VEGFR2).

  10. Hydrogen sulfide (show SQRDL Antibodies) promotes angiogenesis by downregulating miR (show MLXIP Antibodies)-640 and increasing the levels of HIF1A (show HIF1A Antibodies) through the VEGFR2-mTOR (show FRAP1 Antibodies) pathway.

Pig (Porcine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Here we demonstrate that VEGF (show VEGFA Antibodies)-165 mediates MSC (show MSC Antibodies) differentiation into ECs via VEGFR-2-dependent induction of Sox18 (show SOX18 Antibodies), which ultimately coordinates the transcriptional upregulation of specific markers of the EC phenotype

  2. NOS (show NOS Antibodies) stimulation via PI3K, calpain proteases, and SIRT1 (show SIRT1 Antibodies)-dependent deacetylation downstream from VEGFR2 activation contributes to these vasodilator responses.

  3. we analyzed the expression and cellular distribution of Flt-1(VEGFR-1 (show FLT1 Antibodies)) and Flk-1 (KDR/VEGFR-2)in newborn piglet brain

  4. expression of FLK1, CD146 (show MCAM Antibodies) and microvessel density of angiogenesis at the first week of reperfused acute myocardial infarction.

  5. VEGF (show VEGFA Antibodies) supplementation at the late embryonic developmental stage might improve the developmental potential of both IVF (show SCN5A Antibodies) and somatic nuclear transfer preimplantation porcine embryos through its receptors.

  6. The VEGFR2 mRNA was only upregulated in early glomerulogenesis, suggesting that VEGFR2 is important for the vascular growth.

  7. increased placental expression of the VEGF receptor (show FLT1 Antibodies) system is associated with increased placental vascular density observed with the advancement of gestation in the pig

  8. VEGF ligand-receptor system may play an important role in the development and maintenance of the corpus luteum in pigs.

  9. VEGF (show VEGFA Antibodies)/Flk-1/Flt-1 (show FLT1 Antibodies) system is activated during myocardial ischemia reperfusion injury.

  10. Hemodialysis graft placement leads to early increases in wall shear stress, VEGF-A (show VEGFA Antibodies), pro-MMP-9 (show MMP9 Antibodies), MMP-2 (show MMP2 Antibodies), VEGFR-1 (show FLT1 Antibodies), VEGFR-2, and TIMP-1 (show TIMP1 Antibodies), which may contribute to the development of venous stenosis.

Cow (Bovine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Data suggest that galectin-1 (show LGALS1 Antibodies) and VEGFR-2 are expressed at mid-luteal stages in luteal cells of corpus luteum; galectin-1 (show LGALS1 Antibodies) binds directly to asparagine-linked glycans (N-glycans) on VEGFR-2 in luteal cells.

  2. MMP-1 (show MMP1 Antibodies) promotes VEGFR2 expression and proliferation of endothelial cells through stimulation of PAR-1 (show F2R Antibodies) and activation of NF-kappaB (show NFKB1 Antibodies)

  3. Vascular endothelial growth factor receptor-2 activates ADP-ribosylation factor 1 (show ARF1 Antibodies) to promote endothelial nitric-oxide synthase (show NOS3 Antibodies) activation and nitric oxide release from endothelial cells

  4. VEGFR2 mRNA expression was higher at the mid and late luteal stages than at the early I and early II luteal stages, and VEGFR2 protein was higher at the mid and late luteal stages than at estrus (P<0.05)

  5. Alterations in the expression of VEGF-A (show VEGFA Antibodies) and bFGF (show FGF2 Antibodies) systems suggest that angiogenic factors are involved in abnormal placental development in cloned gestations, contributing to impaired fetal development and poor survival rates.

  6. involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt (show AKT1 Antibodies) and endothelial nitric-oxide synthase (eNOS (show NOS3 Antibodies))

  7. Placenta growth factor (show PGF Antibodies) expression is regulated by both VEGF (show VEGFA Antibodies) and hyperglycaemia via VEGFR-2.

  8. ROS (show ROS1 Antibodies) induce expression not only of VEGF (show VEGFA Antibodies) but also of VEGFR2. VEGFR2 increase by ROS (show ROS1 Antibodies) is mainly driven through a NF-kappaB (show NFKB1 Antibodies)-dependent pathway.

  9. By regulating VEGFR2 expression and activation, PKC-epsilon (show PRKCE Antibodies) expression is critical for activation of Akt (show AKT1 Antibodies) and eNOS (show NOS3 Antibodies) by VEGF (show VEGFA Antibodies) and contributes to VEGF (show VEGFA Antibodies)-stimulated Erk (show MAPK1 Antibodies) activation, whereas PKC-alpha (show PKCa Antibodies) has opposite effects.

Rabbit Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Antenatal intratracheal VEGF (show VEGFA Antibodies) administration was associated with an increase in Flk-1 immunoreactivity.

Zebrafish Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Methylglyoxal acts on smaller blood vessels in zebrafish via the VEGF receptor (show FLT1 Antibodies) signaling cascade, thereby describing a new mechanism that can explain vascular complications under hyperglycemia and elevated MG concentrations.

  2. methylation of Lys (show LYZ Antibodies)(1041) promotes the activation of VEGFR-2 and that similar posttranslational modification could also regulate the activity of other receptor tyrosine kinases.

  3. Perturbation of the HSP70 (show HSPA1A Antibodies)-HSP90 (show HSP90 Antibodies) heat-shock protein axis stimulates degradation of endothelial VEGFR2.

  4. Data indicate that the increase in FLT1/sFLT1 (show FLT1 Antibodies) protein levels upon miR-10 (show LILRB2 Antibodies) knockdown inhibited the angiogenic behavior of endothelial cells largely by antagonizing vascular endothelial growth factor receptor 2 signaling: [miR10 (show LILRB2 Antibodies)]

  5. Early Flk1 expression may be induced by cooperative interactions between Gata (show GATA4 Antibodies), Tcf (show HNF4A Antibodies)/Lef, Cdx (show CDX1 Antibodies) and ER71/Etv2 (show ETV2 Antibodies) under the control of Bmp, Wnt (show WNT2 Antibodies) and Fgf signaling.

  6. Using 2 distinct pharmacologic VEGFR2 inhibitors the study shows that rap1b (show RAP1A Antibodies) and VEGFR2 act additively to control angiogenesis in vivo.

  7. Data show that flk1 is not required for proper vasculogenesis and hematopoiesis in zebrafish embryos; however, the disruption of flk1 impairs the formation or function of vessels generated by sprouting angiogenesis

  8. flk1 is a direct target of FoxH1 (show FOXH1 Antibodies); FoxH1 (show FOXH1 Antibodies) is involved in vessel formation in zebrafish.

  9. In the zebrafish, duplicated VegfA (show VEGFA Antibodies) and multiple type III RTKs mediate vascular development.

  10. ISKNV ORF48R can stimulate expression of flk1; knockdown of FLK-1 results in the disappearance of pericardial edema and dilation at the tail region of zebrafish embryos induced by overexpression of ISKNV ORF48R in early stages of embryonic development.

VEGFR2 (KDR) Antigen Profile

Antigen Summary

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.

Alternative names and synonyms associated with VEGFR2 (KDR)

  • vascular endothelial growth factor receptor 2 (vegfr-2) antibody
  • kinase insert domain protein receptor (Kdr) antibody
  • kinase insert domain receptor (Kdr) antibody
  • kinase insert domain receptor (a type III receptor tyrosine kinase) (KDR) antibody
  • kinase insert domain receptor (a type III receptor tyrosine kinase) (Kdr) antibody
  • kinase insert domain receptor (a type III receptor tyrosine kinase) (kdr) antibody
  • kinase insert domain receptor like (kdrl) antibody
  • vascular endothelial growth factor receptor-2 (KDR) antibody
  • 6130401C07 antibody
  • CD309 antibody
  • fk52c05 antibody
  • flk antibody
  • flk-1 antibody
  • FLK/KDR antibody
  • flk1 antibody
  • flk1b antibody
  • kdr antibody
  • kdra antibody
  • kdrb antibody
  • Krd-1 antibody
  • Ly73 antibody
  • si:busm1-205d10.1 antibody
  • si:ch211-254j6.1 antibody
  • si:ch211-278f21.4 antibody
  • sVEGFR-2 antibody
  • VEGFR antibody
  • Vegfr-2 antibody
  • vegfr2 antibody
  • vegfr4 antibody
  • vegr2 antibody
  • wu:fc31a09 antibody
  • wu:fk52c05 antibody

Protein level used designations for KDR

vascular endothelial growth factor receptor 2 , VEGF receptor-2 , fetal liver kinase 1 , kinase NYK , protein-tyrosine kinase receptor flk-1 , soluble vascular endothelial growth factor receptor 2 , vascular endothelial growth factor receptor- 2 , vascular endothelial growth factor receptor-2 , vascular endothelial growth factor receptor-3 , FLK-1 , FLK1 kinase insert domain receptor (VEGF receptor 2) , FLK1 kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGF receptor 2) , kinase insert domain protein receptor , fetal liver kinase-1 , protein-tyrosine kinase receptor Flk-1 , soluble VEGFR2 , tyrosine kinase growth factor receptor , flk-1 type VEGF receptor , VEGFR2 , flk-1 receptor , protein-tyrosine kinase , tyrosine kinase receptor , VEGF receptor-2/Flk-1 , FLK-1b , VEGFR-2 homolog B , fetal liver kinase 1b , kinase insert domain receptor (a type III receptor tyrosine kinase), b , kinase insert domain receptor-B , protein-tyrosine kinase receptor flk-1b , vascular endothelial growth factor receptor 2 homolog B , VEGFR-4 , kinase insert domain receptor-A , kinase insert domain receptor-like , vascular endothelial growth factor receptor 4 , vascular endothelial growth factor receptor kdr-like , vascular endothelial growth factor receptor type 2

GENE ID SPECIES
100136647 Oncorhynchus mykiss
16542 Mus musculus
25589 Rattus norvegicus
3791 Homo sapiens
397311 Sus scrofa
482154 Canis lupus familiaris
395323 Gallus gallus
407170 Bos taurus
100726761 Cavia porcellus
100008607 Oryctolagus cuniculus
554230 Danio rerio
796537 Danio rerio
443087 Ovis aries
Selected quality suppliers for anti-VEGFR2 (KDR) Antibodies
Did you look for something else?